Every Form 4 that CalciMedica, Inc. (CALC) has filed with the SEC in the last 12 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A Form 4 covers the transactions officers, directors and large holders report, so if you follow CALC and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full CALC filings page.
CalciMedica, Inc. (CALC) reported that major stockholder ALAFI CAPITAL CO LLC acquired two new warrant positions on August 19, 2026. The holder received 3,529,192 Series A Warrants exercisable into the same number of common shares at $0.8033 per share and 3,529,192 Series B Warrants at an exercise price of $1.00 per share. The Series A Warrants expire on the earlier of 18 months after the closing date of a related private placement or 30 days following CalciMedica’s public announcement of FDA clearance of its Investigational New Drug Application for CM5480, while the Series B Warrants expire on June 23, 2031. After these transactions, ALAFI CAPITAL CO LLC directly holds 5,112,345 shares of CalciMedica common stock.
CalciMedica, Inc. (CALC) reported that director Allan Shaw received a grant of 10,000 Director Stock Options to purchase common stock. The options have an exercise price of $0.6131 per share and expire on August 18, 2036. According to the vesting terms, 1/12 of the shares vest in equal monthly installments over one year following the grant date, and the award will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders. Following this grant, Shaw holds 10,000 options directly.
CalciMedica, Inc. (CALC) reported that director Alan Glicklich received a grant of 10,000 Director Stock Options to purchase Common Stock at an exercise price of $0.6131 per share. The options expire on August 18, 2036 and are scheduled to vest monthly over one year, and in any event be fully vested by the 2027 annual meeting of stockholders.
CalciMedica, Inc. (CALC) reported that director Frederic Guerard received a grant of 10,000 Director Stock Options on 2026-08-19. Each option allows purchase of one share of common stock at an exercise price of $0.6131 per share and expires on 2036-08-18. According to the vesting terms, 1/12th of the options vest in equal monthly installments over one year following the grant date, and the options will in any case be fully vested on the date of CalciMedica’s 2027 annual meeting of stockholders. Following this grant, Guerard holds 10,000 derivative securities directly.
CalciMedica, Inc. (CALC) reported that director Evgeny Zaytsev, through Bering Partners II, L.P., was granted two series of warrants, each covering 1,450,267 shares of common stock, with exercise prices of $0.8033 and $1.00 per share, respectively. Both warrants become exercisable on or after August 19, 2026 and are subject to a 9.99% beneficial ownership cap. In addition, Zaytsev received a directly held director stock option for 10,000 shares at an exercise price of $0.6131 per share, vesting in monthly installments over one year and expiring on August 18, 2036.
CalciMedica, Inc. (CALC) reported that director Robert N. Wilson received derivative awards on August 19, 2026. He was granted two warrants for 1,182,621 shares each of common stock, with exercise prices of $0.8033 and $1.00 per share, acquired under a Securities Purchase Agreement approved by an independent board committee. These warrants are exercisable starting August 19, 2026, subject to a 19.99% beneficial ownership limitation and specified expiration dates tied to December 25, 2027 or 30 days after public disclosure of FDA clearance of CM5480, and June 25, 2031, respectively. Wilson also received a stock option for 10,000 shares at an exercise price of $0.6131 per share, vesting in 12 equal monthly installments over one year and in any event fully vesting by the 2027 annual meeting of stockholders.
CalciMedica, Inc. (CALC) reported that Chief Medical Officer Sudarshan Hebbar received two warrant awards linked to a Securities Purchase Agreement dated June 23, 2026, with a June 25, 2026 closing, approved by an independent board committee. Each warrant covers 124,486 shares of Common Stock, one with a $0.8033 per-share exercise price expiring as early as December 25, 2027 and the other with a $1.00 exercise price expiring on June 25, 2031. Both become exercisable on or after August 19, 2026 and are subject to a beneficial ownership cap not exceeding 19.99%.
CalciMedica, Inc. (CALC) reported that its Chief Business Officer and director, Eric W. Roberts, acquired two warrant awards to purchase common stock. Each warrant covers 186,729 shares of common stock, one with an exercise price of $0.8033 per share expiring on December 25, 2027, and another with an exercise price of $1.00 per share expiring on June 25, 2031. Both warrants are exercisable on or after August 19, 2026 and were issued under a Securities Purchase Agreement dated June 23, 2026, approved by an independent board committee. Each warrant includes a 19.99% ownership cap, limiting exercises that would cause the holder and its affiliates to exceed that percentage of CalciMedica’s outstanding common stock, subject to adjustment with 61 days’ notice.
CalciMedica, Inc. (CALC) reported that its Chief Executive Officer, A. Rachel Leheny, received two warrant grants on August 19, 2026, each for 186,729 warrants to purchase common stock. One warrant has an exercise price of $0.8033 and expires December 25, 2027, with an earlier end date possible 30 days after public disclosure of clearance of the Investigational New Drug Application for CM5480 by the U.S. Food and Drug Administration. The other has an exercise price of $1.00 and expires June 25, 2031. Both warrants are exercisable on or after August 19, 2026 and are subject to a beneficial ownership limitation not to exceed 19.99%. The warrants were acquired from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, approved by an independent committee of the board.
CalciMedica, Inc. director Evgeny Zaytsev received a grant of stock options covering 20,000 shares of common stock. The options have an exercise price of $0.9654 per share and expire on July 1, 2036. This is a compensation-related award, not an open-market trade. Following the grant, he holds options on 20,000 shares directly. According to the vesting terms, 1/36 of the options vest in equal monthly installments over three years from the grant date.
CalciMedica, Inc. reported that an investment fund affiliated with director and 10% owner Fred A. Middleton increased its stake. On June 25, 2026, Sanderling Venture Partners VI Co-Investment Fund, L.P. acquired 248,972 shares of common stock at $0.8033 per share. The shares were purchased directly from CalciMedica under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent committee of the board. Following this transaction, that fund holds 1,063,272 shares of CalciMedica common stock. Middleton also reports additional direct and indirect holdings, including 36,514 shares held directly and various positions through Sanderling and Golden Triangle entities, while disclaiming beneficial ownership beyond his pecuniary interest.
CalciMedica, Inc. Chief Medical Officer Sudarshan Hebbar acquired 124,486 shares of Common Stock on June 25, 2026 at an indicated price of $0.8033 per share. This brings his direct holdings to 186,025 shares. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent committee of the board of directors.
CalciMedica director Robert N. Wilson acquired 1,182,621 shares of Common Stock at $0.8033 per share. After this transaction, he directly holds 1,604,650 shares. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026, which was approved by an independent board committee and closed on June 25, 2026.
CalciMedica, Inc. director and chief business officer Eric W. Roberts reported a stock award of common shares. He acquired 186,729 shares of common stock at $0.8033 per share in a grant or award transaction. The securities were issued under a Securities Purchase Agreement dated June 23, 2026, with a closing date of June 25, 2026, which was approved by an independent committee of the board of directors.
Following this grant, Roberts directly holds 366,435 common shares. He also has indirect holdings through several entities and retirement accounts, including 316,109 shares held by Valence Investments SPV VI, LLC, 356,989 shares held by Valence Investments SPV IV, LLC, and additional positions in IRA and Roth IRA accounts.
CalciMedica, Inc. director, chief executive officer and 10% owner Rachel A. Leheny reported acquiring 186,729 shares of common stock at $0.8033 per share. The shares were obtained from the company under a Securities Purchase Agreement dated June 23, 2026 with a closing date of June 25, 2026, which was approved by an independent committee of the board. Following this transaction, she directly holds 317,655 common shares. She is also reported as indirectly holding 316,109 shares through Valence Investments SPV VI, LLC, 66,228 through Valence Investments SPV V, LLC, 356,989 through Valence Investments SPV IV, LLC, 3,500 through the Scheibler-Leheny Family Living Trust, and 1,000 through her spouse, while disclaiming beneficial ownership of the Valence entities’ holdings except to the extent of her pecuniary interest.
CalciMedica, Inc. Chief Financial Officer Stephen Bardin received a grant of employee stock options covering 67,728 shares of common stock at an exercise price of $0.585 per share. Beginning April 1, 2026, 1/48th of the option shares vest in equal monthly installments over four years, with vesting starting only after the company files a Form S-8 for shares added under its 2023 Equity Incentive Plan.
CalciMedica, Inc. reported that Chief Medical Officer Sudarshan Hebbar received an employee stock option grant covering 91,173 shares of common stock with an exercise price of $0.585 per share. All 91,173 options are held directly after this grant.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years, and no shares vest until the company files a Form S-8 covering shares added under its 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. reported that Chief Business Officer and 10% owner Eric W. Roberts received an option grant covering 83,358 shares of common stock. The employee stock option has an exercise price of $0.585 per share and expires on April 4, 2036.
According to the vesting terms, beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until the company files a Form S-8 covering shares automatically added under its 2023 Equity Incentive Plan pursuant to an annual evergreen provision.
CalciMedica, Inc. reported that President and COO Michael J. Dunn received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036 and vests in monthly installments over four years, beginning April 1, 2026, after a Form S-8 is filed to cover shares added under the company’s 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. reported that Chief Scientific Officer Kenneth A. Stauderman received an employee stock option grant for 65,124 shares of common stock at an exercise price of $0.585 per share. The option expires on April 4, 2036.
Beginning April 1, 2026, 1/48 of the option vests in equal monthly installments over four years. Vesting will not begin until a Form S-8 is filed covering shares automatically added on January 1, 2026 under the company’s 2023 Equity Incentive Plan evergreen provision.
CalciMedica, Inc. director and chief executive officer Rachel A. Leheny received a grant of 148,482 employee stock options to buy common stock at an exercise price of $0.585 per share. The options expire on April 4, 2036.
Beginning April 1, 2026, 1/48th of the shares subject to the option vest in equal monthly installments over four years. No shares will vest until a Form S-8 is filed for shares automatically added to the company’s 2023 Equity Incentive Plan on January 1, 2026.
CalciMedica, Inc. (CALC) disclosed a director stock option grant on a Form 4. On 10/13/2025, the reporting person received a Director Stock Option (Right to Buy) for 937 shares of common stock at an exercise price of $3.26 per share, coded A for award.
The option has an expiration date of 10/12/2035 and was reported as Direct (D) ownership with 937 derivative securities beneficially owned following the transaction. The filing notes a vesting schedule: beginning October 1, 2025, 1/3 of the shares subject to the option will vest in equal monthly installments. The option was granted at a price of $0 for the derivative security, consistent with standard equity awards.
Eric W. Roberts, identified as a Director, 10% owner and Chief Business Officer of CalciMedica, Inc. (CALC), reported a purchase of 2,500 shares of the issuer's common stock on 09/18/2025 at a price of $3.07 per share. The Form 4 lists multiple existing direct and indirect holdings across custodial and SPV accounts. The filing was signed by an attorney-in-fact on 09/22/2025.